Lite Strategy, Inc. (LITS)
1.04
+0.05
(+5.08%)
USD |
NASDAQ |
Aug 24, 16:00
1.07
+0.03
(+2.88%)
After-Hours: 20:00
Lite Strategy Enterprise Value : 27.25M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 27.25M |
| August 20, 2026 | 25.62M |
| August 19, 2026 | 25.50M |
| August 18, 2026 | 23.46M |
| August 17, 2026 | 23.40M |
| August 14, 2026 | 23.62M |
| August 13, 2026 | 23.94M |
| August 12, 2026 | 24.85M |
| August 11, 2026 | 24.14M |
| August 10, 2026 | 23.05M |
| August 07, 2026 | 24.36M |
| August 06, 2026 | 25.12M |
| August 05, 2026 | 26.04M |
| August 04, 2026 | 25.65M |
| August 03, 2026 | 26.95M |
| July 31, 2026 | 26.33M |
| July 30, 2026 | 27.16M |
| July 29, 2026 | 25.90M |
| July 28, 2026 | 26.56M |
| July 27, 2026 | 26.79M |
| July 24, 2026 | 27.20M |
| July 23, 2026 | 27.32M |
| July 22, 2026 | 28.67M |
| July 21, 2026 | 27.61M |
| July 20, 2026 | 28.67M |
| Date | Value |
|---|---|
| July 17, 2026 | 27.14M |
| July 16, 2026 | 26.56M |
| July 15, 2026 | 27.23M |
| July 14, 2026 | 27.50M |
| July 13, 2026 | 25.71M |
| July 10, 2026 | 27.96M |
| July 09, 2026 | 27.37M |
| July 08, 2026 | 26.80M |
| July 07, 2026 | 26.60M |
| July 06, 2026 | 26.76M |
| July 02, 2026 | 25.87M |
| July 01, 2026 | 26.55M |
| June 30, 2026 | 24.88M |
| June 29, 2026 | 24.43M |
| June 26, 2026 | 24.03M |
| June 25, 2026 | 21.19M |
| June 24, 2026 | 23.15M |
| June 23, 2026 | 23.74M |
| June 22, 2026 | 23.87M |
| June 18, 2026 | 21.56M |
| June 17, 2026 | 24.77M |
| June 16, 2026 | 24.80M |
| June 15, 2026 | 20.60M |
| June 12, 2026 | 18.51M |
| June 11, 2026 | 18.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 2.984B |
| ACADIA Pharmaceuticals, Inc. | 4.195B |
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| Anika Therapeutics, Inc. | 278.32M |
| Savara, Inc. | 1.006B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.69M |
| Total Expenses (Quarterly) | 23.69M |
| EPS Diluted (Quarterly) | -0.6635 |
| Earnings Yield | -193.7% |
| Normalized Earnings Yield | -102.94 |